Researchers put subjects through four rounds of either 1-FIT or 2-FIT screening between 2006 and 2015. About 7,310 1-FIT participants completed at least one round of screening, and 2,269 2-FIT participants completed at least one round of screening.
What they found:
1. The 1-FIT cohort had a 19.2 percent cumulative positive rate, lower than the 28.5 percent rate the 2-FIT cohort posted.
2. Cumulative positive predictive value was higher in the 1-FIT cohort (33 percent) than the 2-FIT cohort (24.2 percent).
3. Diagnostic yield of advanced neoplasia was higher in the 2-FIT cohort (4.7 percent) than the 1-FIT cohort (4.4 percent).
4. Eight people in the 1-FIT cohort and two people in the 2-FIT cohort had interval colorectal cancers.
Researchers said one-sample FIT programs were preferred to two-sample FIT programs because, “Four rounds of 2-FIT screening with a low faecal haemoglobin cutoff level did not result in a significant increase in diagnostic yield or a decrease in interval colorectal cancers compared with 1-FIT, despite higher colonoscopy demand.”
More articles on gastroenterology:
3 states considering ASC-related reforms
9 financial benchmarks for ASCs to track
Consolidation, new technologies & more: top 4 challenges ASCs face in the outpatient market
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
